Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome
- PMID: 36544055
- DOI: 10.1111/apt.17356
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome
Abstract
Background: Little is known about associations with reduced quality of life in irritable bowel syndrome (IBS) or impact of IBS on quality of life compared with other chronic conditions.
Methods: We collected demographic, gastrointestinal and psychological symptoms, healthcare usage, direct healthcare costs, impact on work and activities of daily living data from 752 individuals with Rome IV-defined IBS. We used the irritable bowel syndrome quality of life (IBS-QOL) and the EQ-5D-5L questionnaires to examine characteristics associated with lower quality of life.
Results: The mean IBS-QOL among all 752 individuals with Rome IV IBS was 48.4 (SD 22.3) and the mean EQ-5D score was 0.570 (SD 0.283), the latter being comparable to people with stroke, leg ulcers or chronic obstructive pulmonary disease. Lower levels of both disease-specific and generic quality of life were associated with severe IBS symptom scores, abnormal anxiety or depression scores, and higher somatoform symptom-reporting and gastrointestinal symptom-specific anxiety scores (p < 0.001 for all analyses). Those with lower quality of life had significantly higher healthcare usage and direct healthcare costs and more impairment in work and activities of daily living (p < 0.01 for all analyses). Avoidance of alcohol, lower educational level, abnormal anxiety, depression or somatoform symptom-reporting scores, and impairment in social leisure activities, home management or maintaining close relationships were all independently associated with lower quality of life.
Conclusion: IBS has a substantial impact on the quality of life of those affected, and worse than observed in some severe chronic organic conditions.
Keywords: EQ-5D; EuroQOL; IBS-QOL; irritable bowel syndrome; quality of life.
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply.Aliment Pharmacol Ther. 2023 Mar;57(6):725-726. doi: 10.1111/apt.17404. Aliment Pharmacol Ther. 2023. PMID: 36821754 No abstract available.
-
Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here?Aliment Pharmacol Ther. 2023 Mar;57(6):723-724. doi: 10.1111/apt.17391. Aliment Pharmacol Ther. 2023. PMID: 36821756 No abstract available.
-
Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients?Aliment Pharmacol Ther. 2023 May;57(10):1188-1189. doi: 10.1111/apt.17485. Aliment Pharmacol Ther. 2023. PMID: 37094307 No abstract available.
-
Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply.Aliment Pharmacol Ther. 2023 May;57(10):1190-1191. doi: 10.1111/apt.17497. Aliment Pharmacol Ther. 2023. PMID: 37094324 No abstract available.
Similar articles
-
Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden.Neurogastroenterol Motil. 2024 Apr;36(4):e14756. doi: 10.1111/nmo.14756. Epub 2024 Feb 6. Neurogastroenterol Motil. 2024. PMID: 38321517
-
Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.Aliment Pharmacol Ther. 2023 May;57(10):1083-1092. doi: 10.1111/apt.17465. Epub 2023 Mar 13. Aliment Pharmacol Ther. 2023. PMID: 36914979
-
Impact of Rome IV irritable bowel syndrome on work and activities of daily living.Aliment Pharmacol Ther. 2022 Sep;56(5):844-856. doi: 10.1111/apt.17132. Epub 2022 Jul 6. Aliment Pharmacol Ther. 2022. PMID: 35794733 Free PMC article.
-
Frequency of irritable bowel syndrome in spondyloarthritis: a multicentric cross-sectional study and meta-analysis.RMD Open. 2024 Jan 12;10(1):e003836. doi: 10.1136/rmdopen-2023-003836. RMD Open. 2024. PMID: 38216286 Free PMC article.
-
Review article: the economic impact of the irritable bowel syndrome.Aliment Pharmacol Ther. 2014 Nov;40(9):1023-34. doi: 10.1111/apt.12938. Epub 2014 Sep 9. Aliment Pharmacol Ther. 2014. PMID: 25199904 Review.
Cited by
-
Common misconceptions and controversies in the management of irritable bowel syndrome.Nat Rev Gastroenterol Hepatol. 2025 Jul;22(7):517-526. doi: 10.1038/s41575-025-01065-9. Epub 2025 Apr 25. Nat Rev Gastroenterol Hepatol. 2025. PMID: 40281279 Review.
-
The gut microbiome in disorders of gut-brain interaction.Gut Microbes. 2024 Jan-Dec;16(1):2360233. doi: 10.1080/19490976.2024.2360233. Epub 2024 Jul 1. Gut Microbes. 2024. PMID: 38949979 Free PMC article. Review.
-
Concordance between Rome III and Rome IV criteria in irritable bowel syndrome.Indian J Gastroenterol. 2024 Dec;43(6):1079-1081. doi: 10.1007/s12664-024-01624-z. Indian J Gastroenterol. 2024. PMID: 38954364 No abstract available.
-
Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial.Nutrients. 2024 Oct 1;16(19):3333. doi: 10.3390/nu16193333. Nutrients. 2024. PMID: 39408300 Free PMC article. Clinical Trial.
-
Antibiotics and Probiotics for Irritable Bowel Syndrome.Drugs. 2023 Jun;83(8):687-699. doi: 10.1007/s40265-023-01871-y. Epub 2023 May 15. Drugs. 2023. PMID: 37184752 Review.
References
REFERENCES
-
- Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-17.
-
- Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99-114 e3.
-
- Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675-88.
-
- Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133-46.
-
- Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources